Condition
Acute Lymphatic Leukemia
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Recruiting2
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06508775Not ApplicableRecruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06680661Phase 2Recruiting
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
NCT05250869Completed
Comparative Quantification of MTX and Its Metabolites Post Glucarpidase
NCT01111396UnknownPrimary
Longitudinal Investigation of Hippocampal Function and Morphology in Acute Lymphatic Leukemia (ALL) Patients Treated With Chemotherapy
Showing all 4 trials